J. C. Hsu

Towards the Clinical Translation of a Silver Sulfide Nanoparticle Contrast Agent: Large Scale Production with a Highly Parallelized Microfluidic Chip

This paper develops a scalable microfluidic method to produce silver sulfide nanoparticles for clinical imaging, showing high-quality output and efficient in vivo clearance.

A biodegradable "one-for-all" nanoparticle for multimodality imaging and enhanced photothermal treatment of breast cancer

This paper develops AgPCPP, biodegradable nanoparticles that enhance NIR imaging and photothermal therapy for breast cancer, showing safety and efficacy in vivo.

Theranostic gold in a gold cage nanoparticle for photothermal ablation and photoacoustic imaging of skin and oral infections

This study develops a theranostic gold nanoparticle for detecting and treating biofilm infections using photothermal ablation and photoacoustic imaging, showing superior efficacy against oral and wound infections compared to chlorhexidine.

Quantum CART (qCART), a piggyBac-based system for development and production of virus-free multiplex CAR-T cell therapy

The paper introduces a virus-free multiplex CAR-T cell therapy system called qCART, integrating four platforms to improve CAR-T development and manufacturing.

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using qCART, the Quantum pBac-based CAR-T system

This paper demonstrates the efficient manufacturing of CD20/CD19 dual-targeted, iCasp9-regulatable CAR-TSCM cells using the virus-free qCART system, showing robust tumor eradication and safety.

Quantum pBac: An effective, high-capacity piggyBac-based gene integration vector system for unlocking gene therapy potential

This paper develops a virus-free gene therapy vector system, Quantum pBac, which improves transposition efficiency and payload capacity for CAR-T cell production.

Long SARS-CoV-2 nucleocapsid sequences in blood monocytes collected soon after hospital admission

The paper detects long SARS-CoV-2 nucleocapsid sequences in blood monocytes of patients within 2-6 days of hospital admission, suggesting early viral dissemination by myeloid cells.

A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells

This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

This study designs and synthesizes potent SARS-CoV-2 main protease inhibitors, with some showing IC50 values below 100 nM and high virus inhibition potency in cell assays.